Aralez Pharmaceuticals Inc. (ARLZ) PT Set at $12.00 by Guggenheim
Separately, Chardan Capital restated a buy rating and issued a $10.00 target price on shares of Aralez Pharmaceuticals in a research report on Sunday, August 14th.
Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 4.81 on Monday. Aralez Pharmaceuticals has a 12 month low of $3.10 and a 12 month high of $8.59. The firm’s market cap is $313.81 million. The stock’s 50 day moving average is $5.26 and its 200 day moving average is $4.21.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The business’s revenue for the quarter was up 142.3% on a year-over-year basis. Equities research analysts expect that Aralez Pharmaceuticals will post ($1.06) EPS for the current year.
In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total value of $873,000.00. Following the completion of the sale, the director now owns 669,094 shares in the company, valued at $3,894,127.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.77% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can bought a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $100,000. Advisor Group Inc. bought a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $118,000. Knott David M bought a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $124,000. Alpine Partners VI LLC bought a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $133,000. Finally, LMR Partners LLP bought a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $145,000. Hedge funds and other institutional investors own 49.63% of the company’s stock.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.